Castrate-Resistant Prostate Cancer
Oncology
4
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Tevacustirsen sodium
NovartisBEZ235
Ionis PharmaceuticalsISIS EIF4E Rx
Clinical Trials (3)
Total enrollment: 133 patients across 3 trials
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Start: Mar 2010Est. completion: Mar 201314 patients
Phase 3Terminated
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Start: Jan 2013Est. completion: Aug 20166 patients
Phase 1/2Terminated
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
Start: Nov 2010Est. completion: Dec 2013113 patients
Phase 1/2Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
9m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
9m ago
Office Administrator
SystImmune
9m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
19m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
23m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
23m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space